STBD1

Across TCGA pan-cancer cohorts, STBD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STBD1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STBD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STBD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where STBD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.568	1.000	.001	34	view →
PDAC	OS	Median	IV	0.381	0.951	.006	16	view →
LUAD	OS	Tertile	All	0.541	0.983	.005	15	view →
GBM	OS	Tertile	All	0.712	0.945	.005	14	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STBD1–CCRCC (DFS)

Open the CCRCC breakdown →